Skip to main content

Table 1 Sample’s baseline characteristics, according to the presence of Clinical Lipodystrophy (CL)

From: Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test – which method to choose for the diagnosis?

  With CL Without CL P value
n (%) 115 (52.3) 105 (47.7)  
Sex [n (%)]    0.099
 Male 76 (66.1) 57 (54.3)  
 Female 39 (33.9) 48 (45.7)  
Age [years, mean (SD)] 47.5 (11.3) 43.8 (11.5) 0.017
Duration of HIV infection [years, median (IR)] 9 (5) 6 (6) 0.001
cART [years, median (IR)] 8 (5) 5 (5.5) < 0.001
Weight [Kg, mean (SD)] 64.1 (12.8) 73.9 (12.6) < 0.001
Height [m, mean (SD)] 1.7 (0.1) 1.7 (0.1) 0.765
BMI [(kg/m2), mean (SD)] 23.6 (3.8) 27.2 (4.5) < 0.001
Waist circumference [cm, mean (SD)] 88.4 (10.8) 95.1 (12.1) < 0.001
CD4 cell count [cells/mm3, median (IR)] 554 (385) 479 (300) 0.238
HIV RNA (<50) [n (%)] 100 (100) 92 (100)  
Hepatitis C co-infection [n (%)] 34 (29.8) 30 (29.4) 0.999
Hypertension [n (%)] 45 (39.1) 23 (21.9) 0.009
HIV risk factor [n (%)]    0.162
 Intravenous drug user 1 (25) 3 (15.8)  
 Homosexual contact 0 (0) 2 (10.5)  
 Heterosexual contact 2 (50) 14 (73.7)  
 Others 1 (25) 0 (0)  
CDC clinical categories [n (%)]    0.389
 A 63 (54.8) 56 (53.3)  
 B 1 (0.9) 4 (3.8)  
 C 51 (44.3) 45 (42.9)  
ART [n (%)]    
 IP 61 (53) 62 (59) 0.447
 NNRTI 55 (47.8) 47 (44.8) 0.749
 NRTI 113 (98.3) 97 (92.4) 0.051
Smoking history [n (%)]    0.032
 Never 38 (33.3) 53 (50.5)  
 Current 56 (49.1) 36 (34.3)  
 Former 20 (17.5) 16 (15.2)  
Total cholesterol [mg/dL, mean (SD)] 221.9 (53.2) 227.8 (57.8) 0.433
LDL- cholesterol [mg/dL, mean (SD)] 129.4 (48.1) 140 (45.4) 0.097
HDL- cholesterol [mg/dL, mean (SD)] 46.5 (14.8) 49.5 (13.3) 0.123
Triglycerides [mg/dL, median (IR)] 215.5 (214.5) 171 (154) 0.007
Statin use [n (%)] 33 (28.7) 13 (12.4) 0.005
Fibrate use [n (%)] 41 (35.7) 24 (22.9) 0.054
  1. CL clinical lipodystrophy, cART combination antiretroviral therapy, BMI body mass index, ART antiretroviral therapy, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, HOMA homeostatic model assessment, QUICKI quantitative insulin sensitivity check index, SD standard deviation, IR interquartile range